131 related articles for article (PubMed ID: 17722195)
1. Optimal response-adaptive designs for continuous responses in phase III trials.
Biswas A; Bhattachary R; Zhang L
Biom J; 2007 Dec; 49(6):928-40. PubMed ID: 17722195
[TBL] [Abstract][Full Text] [Related]
2. Optimal response-adaptive designs for normal responses.
Biswas A; Bhattacharya R
Biom J; 2009 Feb; 51(1):193-202. PubMed ID: 19197961
[TBL] [Abstract][Full Text] [Related]
3. Covariate-adjusted adaptive designs for continuous responses in a phase III clinical trial: recommendation for practice.
Biswas A; Huang HH; Huang WT
J Biopharm Stat; 2006; 16(2):227-39. PubMed ID: 16584069
[TBL] [Abstract][Full Text] [Related]
4. Shift-invariant target in allocation problems.
Mandal S; Biswas A
Stat Med; 2014 Jul; 33(15):2597-611. PubMed ID: 24549681
[TBL] [Abstract][Full Text] [Related]
5. Covariate-adjusted response-adaptive designs for longitudinal treatment responses: PEMF trial revisited.
Biswas A; Park E; Bhattacharya R
Stat Methods Med Res; 2012 Aug; 21(4):379-92. PubMed ID: 20974667
[TBL] [Abstract][Full Text] [Related]
6. Adaptive biased-coin designs for skewing the allocation proportion in clinical trials with normal responses.
Atkinson AC; Biswas A
Stat Med; 2005 Aug; 24(16):2477-92. PubMed ID: 16007571
[TBL] [Abstract][Full Text] [Related]
7. Response-adaptive designs for continuous treatment responses in phase III clinical trials: A review.
Biswas A; Bhattacharya R
Stat Methods Med Res; 2016 Feb; 25(1):81-100. PubMed ID: 22425657
[TBL] [Abstract][Full Text] [Related]
8. Bayesian adaptive biased-coin designs for clinical trials with normal responses.
Atkinson AC; Biswas A
Biometrics; 2005 Mar; 61(1):118-25. PubMed ID: 15737084
[TBL] [Abstract][Full Text] [Related]
9. An urn model for odds-ratio-based response-adaptive phase III clinical trials for two or more treatments.
Basak GK; Biswas A; Volkov S
J Biopharm Stat; 2009 Sep; 19(5):838-56. PubMed ID: 20183447
[TBL] [Abstract][Full Text] [Related]
10. Dose finding designs for continuous responses and binary utility.
Fedorov VV; Wu Y
J Biopharm Stat; 2007; 17(6):1085-96. PubMed ID: 18027218
[TBL] [Abstract][Full Text] [Related]
11. Adaptive designs for confirmatory clinical trials.
Bretz F; Koenig F; Brannath W; Glimm E; Posch M
Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
Moatti M; Chevret S; Zohar S; Rosenberger WF
Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
[TBL] [Abstract][Full Text] [Related]
13. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials.
Roth T; van Seventer R; Murphy TK
Curr Med Res Opin; 2010 Oct; 26(10):2411-9. PubMed ID: 20812792
[TBL] [Abstract][Full Text] [Related]
14. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
15. Multiple-objective response-adaptive repeated measurement designs in clinical trials for binary responses.
Liang Y; Li Y; Wang J; Carriere KC
Stat Med; 2014 Feb; 33(4):607-17. PubMed ID: 24038318
[TBL] [Abstract][Full Text] [Related]
16. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief.
Stacey BR; Barrett JA; Whalen E; Phillips KF; Rowbotham MC
J Pain; 2008 Nov; 9(11):1006-17. PubMed ID: 18640074
[TBL] [Abstract][Full Text] [Related]
17. Sequential designs for phase III clinical trials incorporating treatment selection.
Stallard N; Todd S
Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
[TBL] [Abstract][Full Text] [Related]
18. Optimal dose-finding designs with correlated continuous and discrete responses.
Fedorov V; Wu Y; Zhang R
Stat Med; 2012 Feb; 31(3):217-34. PubMed ID: 22162014
[TBL] [Abstract][Full Text] [Related]
19. Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia.
Sharma U; Griesing T; Emir B; Young JP
Am J Ther; 2010; 17(6):577-85. PubMed ID: 20393345
[TBL] [Abstract][Full Text] [Related]
20. Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.
Mauer M; Collette L; Bogaerts J;
Eur J Cancer; 2012 Jun; 48(9):1386-91. PubMed ID: 22281098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
